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vs. 64.9 for Tlysis and 66.1 for medical therapy(each p < 0.05) and were less
often women, 20.0%, vs. 36.2% and 36.1 %, respectively, (each p < 0.05).
Time to presentation was significantly longer for medically treated pts: 13.8h
vs. 4.4h for Tlysis and 3.3h for 10 PTCA (each p < 0.001). Delay> 12 hours
was the reason cited most often for pts not treated with thrombolysis. In-
hospital mortality is shown. Recurrent MI was similar in the 3 groups, 4.2%.
Conclusions: 11) In 1994 in the U.S., reperfusion therapy was used in 71 % of
pts with ST elevation MI at these hospitals. (2) The potential underutilization
of l' PTCA in women deserves further study. (3) Early mortality was similar
for Tlysis and l' PTCA, but highest for medically treated pts, which supports
further expansion of reperfusion therapy in ST elevation MI (including use of
strategies to shorten patient time to presentation) and the need for improved
medical therapies for thrombolytic ineligible patients.
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Does a Less Restrictive Indication for Thrombolytic
Therapy Cause More Iatrogenic Complications in
Acute Myocardial Infarction?
Udo Burczyk, Jbrg Rustige. Rudolf Schiele, Armin Koch, Rainer Uebis.
Jochen Senges, ALKK-Study-Group. Herzzentrum Ludwigshafen, Department of
Cardiology, Germany
Purpose: In consideration of possible severe complications thrombolytic
agents are administered to only 30% of patients with acute myocardial in-
farction (AMI) admitted to coronary care units in Western Europe. "The 60-
Minutes Myocardial Infarction Project" therefore investigates the effect of a
higher lysis rate (LR) on the frequency of complications.
Methods: The multicenter nationwide study includes 154 hospitals in Ger-
many. During an 8-month period 4650 consecutive patients with proven
transmural AMI were enrolled and complications occurring within 48 hours
after admission were registered for clinical centers with a low and high LR
1~50% versus >50%).
Results:
clinical centers: all LR < 50% LR > 50%
complications (within 48 h): n ~ 4650 n = 2768 n ~ 1882
death 8.0% 8.3% 7.5%
hemorrhagic stroke 0.4% 0.5% 0.2%
ventricular rupture 0.4% 0.4% 0.4%
moderate bleeding 2.4% 1.8% 3,3%
allergic reaction 0.8% 0.5% 1.3%
Christopher Granger. Harvey White. Maarten Simoons, Douglas Weaver, Joel Gore,
Phil Aylward. Gabriel Barbash. Kerry Lee. Robert Califf. GUSTO Investigators.
Duke University Medical Center; Durham, NC
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1755-51 Risk Factors for Stroke Following Thrombolytic
Therapy: Case-Control Study from the GUSTO Trial
In order to determine risk factors for stroke beyond the standard known fac-
tors of age. presenting blood pressure, weight. sex, and history of hyper-
tension which were collected on all patients in the GUSTO Trial. additional
data were collected for the 592 patients suffering stroke as well as 548 age-
matched controls. Odds ratios 195% el) were as follows:
For hemorrhagic stroke
7.6129-201
2.8 (1.1--6.61
3.4 (1.2-10)
0.96 (0.41-22)
1.8 (0.40-7.9)
1.6 (091-2.9)
1.3 (0.88-1.8)
1.6111-2.4)
For any stroke
3.9 (1.4-11)
4.0 (2.0-8.1)
2.2 (0.76--B.3)
30 (1.8-50)
2.7 (0.88-8.3)
15 (0.97-25)
1.5(1.1-20)
12 (0.88-1.71
Facial or head trauma within 2 wks
History of stroke
Dementia
Atrial fibrillation
Warfarin use
Nonsteroidal anti-inflam matory use
Calcium blocker use
Beta blocker use
Both groups were similar in age, sex and coexisting diseases.
Conclusions: 1. 48-hour mortality was lower in clinical centers with a higher
LR. 2. Severe complications showed no significant difference. 3. Minor com-
plications were significantly more frequent in clinical centers with a higher
LR. 4. These results support a less restrictive indication for thrombolytic ther-
apy in AMI based on individual benefit-risk evaluation.
David J. Moliterno. Christopher Granger, Robert M. Califf. John M. Elliott.
Amanda Stebbins, Eric J. Topol, GUSTO Investigators. The Cleveland Clinic
Foundation. Cleveland, OH
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Previous studies of thrombolysis in acute myocardial infarction (AMI) have
noted lower efficacy in heavy patients and a higher incidence of bleeding
complications among lighter patients. In the GUSTO trial of 41 ,021 patients
receiving either streptokinase, a weight-adjusted dose of t-PA. or combina-
tion therapy for AMI, we prospectively collected data on patient weight and
postulated prognostic value based on this variable. Patients with increased
body mass were hypothesized to have reduced thrombolytic efficacy. Sur-
vival, along with moderate and severe bleeding complications, were there-
fore analyzed according to weight subgroups separated into deciles. Para-
doxically, inverse relationships between patient body weight and both bleed-
ing and mortality were demonstrated regardless of thrombolytic treatment
strategy. Moreover, in a multivariable model of predictors of mortality, pa-
tient body weight added significant independent prognostic information (X 2
= 19, P < 0.0001). In conclusion, an inverse relationship to mortality was
present throughout the weight range of patients. In contrast to previous ob-
servations, heavy weight patients actually have an improved prognosis.
1755-31 Improved Prognosis for Heavy Weight Patients
Receiving Thrombolysis in Acute Myocardial
Infarction - Bigger is Better: Results from GUSTO
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These findings suggest that recent facial or head trauma is a strong risk
factor for hemorrhagic stroke following thrombolytic therapy, and therefore
should generally be considered to be a contraindication to thrombolytic
therapy. History of stroke predisposes to both any stroke and hemorrhagic
stroke, and dementia appears to predispose to hemorrhagic stroke.
1755-61 Neurosurgical Evacuation for Intracranial
Hemorrhage Associated with Improved Outcome in
GUSTO
Kenneth W. Mahaffey. Harvey D. White. Christopher B. Granger, Robert M. Califf,
Joel M. Gore. W. Douglas Weaver. Maarten L. Simoons. Gabriel!. Barbash,
Michael A. Sloan, Eric J. Topol, GUSTO Investigators. Duke University Medical
Center. Durham, NC
In order to evaluate the impact of neurosurgical evacuation of intracranial
hemorrhage IICH) following thrombolytic therapy for acute myocardial infarc-
tion, we analyzed the 268 patients with ICH in the GUSTO Trial. In-hospital
mortality was 60% with only 13% of patients discharged with minor or no
disability. Of the 268 patients, 47 had neurosurgical intervention with the fol-
lowing results:
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